Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,784,840
  • Shares Outstanding, K 124,637
  • Annual Sales, $ 0 K
  • Annual Income, $ -402,270 K
  • EBIT $ -529 M
  • EBITDA $ -554 M
  • 60-Month Beta 0.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.82

Options Overview Details

View History
  • Implied Volatility 56.86% ( -5.42%)
  • Historical Volatility 42.48%
  • IV Percentile 69%
  • IV Rank 25.23%
  • IV High 135.29% on 08/06/24
  • IV Low 30.38% on 09/24/24
  • Put/Call Vol Ratio 2.33
  • Today's Volume 848
  • Volume Avg (30-Day) 91
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 12,250
  • Open Int (30-Day) 12,515

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.32
  • Number of Estimates 4
  • High Estimate -0.91
  • Low Estimate -2.17
  • Prior Year -1.82
  • Growth Rate Est. (year over year) +27.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.46 +2.45%
on 12/19/24
94.76 -8.69%
on 12/02/24
+0.57 (+0.66%)
since 11/20/24
3-Month
84.46 +2.45%
on 12/19/24
118.62 -27.05%
on 10/16/24
-28.65 (-24.87%)
since 09/20/24
52-Week
53.83 +60.75%
on 01/05/24
121.06 -28.52%
on 09/19/24
+27.00 (+45.36%)
since 12/20/23

Most Recent Stories

More News
New Vaccine Technologies Lead the Charge as Global Immunization Efforts Evolve

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – According to the World Health...

PCVX : 86.53 (+0.37%)
BVAXF : 0.0475 (+2.15%)
BIOV.CN : 0.0650 (+8.33%)
GILD : 92.57 (+1.62%)
GOVX : 2.29 (-1.29%)
ARCT : 15.48 (+4.31%)
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank

Jefferies analysts have set the S&P 500 (SNPINDEX: ^GSPC) with a 2025 target of 6,000. That forecast implies about 1% downside from its current level of 6,050, which ranks among the most bearish outlooks...

PCVX : 86.53 (+0.37%)
JPM : 237.60 (+1.99%)
$SPX : 5,930.85 (+1.09%)
FTAI : 133.49 (+1.79%)
JEF : 76.22 (+1.28%)
SFM : 131.70 (-2.22%)
MLI : 80.18 (+0.87%)
GS : 566.10 (+2.19%)
INSM : 70.44 (+1.48%)
VTWO : 90.05 (+0.93%)
Why Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy”

These two biotech companies look poised to deliver in the coming year.

PCVX : 86.53 (+0.37%)
$SPX : 5,930.85 (+1.09%)
MRK : 98.05 (-1.48%)
AIT : 240.58 (-1.18%)
PFE : 26.36 (+2.29%)
Insider Sale: CHIEF EXECUTIVE OFFICER of $PCVX (PCVX) Sells 222 Shares

GRANT PICKERING, the CHIEF EXECUTIVE OFFICER of $PCVX ($PCVX), sold 222 shares of the company on 12-09-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.2%...

PCVX : 86.53 (+0.37%)
Insider Sale: SVP of $PCVX (PCVX) Sells 1,435 Shares

Mikhail Eydelman, the SVP of $PCVX ($PCVX), sold 1,435 shares of the company on 12-05-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.3% of their shares....

PCVX : 86.53 (+0.37%)
Insider Sale: CHIEF OPERATING OFFICER of $PCVX (PCVX) Sells 1,101 Shares

Jim Wassil, the CHIEF OPERATING OFFICER of $PCVX ($PCVX), sold 1,101 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.5% of...

PCVX : 86.53 (+0.37%)
Insider Sale: CHIEF EXECUTIVE OFFICER of $PCVX (PCVX) Sells 2,242 Shares

GRANT PICKERING, the CHIEF EXECUTIVE OFFICER of $PCVX ($PCVX), sold 2,242 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.5%...

PCVX : 86.53 (+0.37%)
Vaxcyte Initiates Phase 2 Study for VAX-31 Pneumococcal Vaccine in Infants, Anticipates Topline Data in 2026

Vaxcyte initiates Phase 2 study for VAX-31, targeting enhanced protection against pneumococcal disease in infants. Topline data expected by mid-2026.Quiver AI SummaryVaxcyte, Inc. has initiated a Phase...

PCVX : 86.53 (+0.37%)
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

PCVX : 86.53 (+0.37%)
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst

In general, the S&P 500 (SNPINDEX: ^GSPC) is the preferred stock market barometer for large-cap companies, while the Russell 2000 is the preferred stock market barometer for small-cap companies. Specific...

PCVX : 86.53 (+0.37%)
JPM : 237.60 (+1.99%)
$SPX : 5,930.85 (+1.09%)
FTAI : 133.49 (+1.79%)
VOO : 545.04 (+1.13%)
SFM : 131.70 (-2.22%)
MLI : 80.18 (+0.87%)
GS : 566.10 (+2.19%)
INSM : 70.44 (+1.48%)
VTWO : 90.05 (+0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

See More

Key Turning Points

3rd Resistance Point 90.85
2nd Resistance Point 89.87
1st Resistance Point 88.20
Last Price 86.53
1st Support Level 85.56
2nd Support Level 84.58
3rd Support Level 82.91

See More

52-Week High 121.06
Fibonacci 61.8% 95.38
Fibonacci 50% 87.44
Last Price 86.53
Fibonacci 38.2% 79.51
52-Week Low 53.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar